OB/GYN Guide

Clinical Features & History Taking

A detailed antenatal history sets the foundation for a targeted physical exam. Key elements include:

• Last Menstrual Period (LMP): Determines gestational age and expected date of delivery.
• Obstetric History: Gravidity, parity, previous complications (miscarriages, preterm labour, gestational diabetes, pre-eclampsia).
• Medical History: Chronic conditions (hypertension, diabetes, thyroid disorders), allergies, medications.
• Social History: Smoking, alcohol intake, nutritional status, support systems.
• Symptoms: Vaginal bleeding, abdominal pain, reduced fetal movements, nausea/vomiting, urinary complaints.

Examination Technique

The physical examination in pregnancy should be systematic and respectful. The key components include:

1. General Observation: Assess for pallor, edema, and signs of systemic disease.
2. Vital Signs: Blood pressure, pulse, temperature, and weight measurement.
3. Abdominal Inspection: Look for distension, skin changes (stretch marks), and scars.
4. Palpation: Use Leopold’s maneuvers to determine fetal lie, presentation, and engagement. Measure fundal height as an indirect measure of uterine growth.
5. Auscultation: Assess the fetal heart rate using a Doppler device or fetoscope. Normal range is 110-160 bpm.

OSCE Tips for Antenatal Examination

In an OSCE, you will be assessed not only on your technical ability but also on communication and patient care. Key pointers include:

1. Introduce yourself, confirm the patient’s identity, and explain the procedure clearly.
2. Ensure proper draping and privacy at all times.
3. Obtain consent and ask if the patient has any discomfort before starting.
4. Verbalize each step of the exam as you perform it.
5. Be systematic—start with general observation and vital signs, then proceed to the abdominal examination.
6. Conclude by summarizing your findings and offering reassurance or further management steps as needed.

Flashcards: Antenatal Examination

Click on each card to reveal the answer.

Aetiology & Risk Factors of PMB and IMB

Aetiology of Postmenopausal Bleeding (PMB):

The primary goal is to exclude malignancy. Common causes include:

• Endometrial Atrophy (Most common, ~50-60%): Thinning of the endometrial and vaginal lining due to low oestrogen levels, making it fragile and prone to bleeding.
• Exogenous Oestrogens (HRT):
  • Unopposed Oestrogen (in women with a uterus): Leads to endometrial proliferation and hyperplasia, a major risk for cancer.
  • Combined HRT: Unscheduled bleeding can occur, especially with continuous combined regimens in the first few months, or if the progestogen component is insufficient.
• Endometrial Polyps (~10-30%): Benign localised overgrowths of endometrial tissue. Can occasionally contain hyperplasia or, rarely, carcinoma.
• Endometrial Hyperplasia (~5-10%): Proliferation of endometrial glands, leading to a thickened endometrium. Classified as with or without atypia. Atypical hyperplasia is a premalignant condition with a significant risk of progression to cancer.
• Endometrial Carcinoma (~5-10%): The most serious cause. Risk increases with age and other risk factors.
• Cervical Polyps/Carcinoma: Less common causes of PMB, more typically present with PCB.
• Vaginal Atrophy: Similar to endometrial atrophy, vaginal tissues can become dry, thin, and bleed easily.
• Other Uterine Malignancies: E.g., uterine sarcoma (rare).
• Tamoxifen Use: Has a weak oestrogenic effect on the endometrium, increasing risk of polyps, hyperplasia, and cancer.
• Anticoagulants/Bleeding Disorders: Can exacerbate bleeding from any minor lesion.

Aetiology of Intermenstrual Bleeding (IMB):

Causes are diverse and depend on age, sexual activity, and contraceptive use:

• Pregnancy-Related (Must Exclude First!): Implantation bleeding, threatened/inevitable/incomplete miscarriage, ectopic pregnancy.
• Hormonal/Ovulatory Dysfunction:
  • Anovulatory cycles: Common in perimenopause, PCOS, thyroid disorders, stress, extreme weight changes. Leads to unopposed oestrogen and irregular shedding.
  • Ovulatory bleeding: Physiological mid-cycle spotting due to oestrogen dip around ovulation.
  • Luteal phase defect: Insufficient progesterone production.
• Iatrogenic/Contraceptive-Related:
  • Combined Oral Contraceptives (COCP): Breakthrough bleeding, especially in first 3 months or with missed pills.
  • Progestogen-Only Methods (POP, implant, injection, IUS – Mirena): Irregular bleeding is a very common side effect due to effects on endometrial stability.
  • Emergency Contraception.
  • Anticoagulants, some psychotropics.
• Structural Lesions (Benign):
  • Cervical Ectropion/Erosion: Glandular cells on ectocervix, prone to bleeding, especially PCB.
  • Cervical Polyps.
  • Endometrial Polyps.
  • Uterine Fibroids (Leiomyomas): Especially submucosal or intracavitary fibroids distorting the endometrial cavity.
  • Adenomyosis: Endometrial tissue within the myometrium.
• Infections/Inflammation:
  • Cervicitis: Chlamydia, Gonorrhoea, Trichomonas.
  • Pelvic Inflammatory Disease (PID): Often with IMB, pain, discharge.
  • Endometritis.
• Malignancy/Premalignancy (Less common in younger women, but risk increases with age):
  • Cervical Intraepithelial Neoplasia (CIN) / Cervical Cancer.
  • Endometrial Hyperplasia / Cancer (especially if anovulatory cycles and other risk factors are present).
  • Vaginal/Vulval cancer (rare).

Comprehensive Assessment & Investigation Strategy

Systematic History Taking:

A detailed history is the cornerstone of diagnosis. Tailor questions based on PMB vs. IMB.

Key Areas to Cover:

• Details of the Bleeding:
  • PMB: Confirm LMP (>12 months ago). First episode or recurrent? Amount (spotting vs. heavy)? Provoking factors (e.g., post-coital)? Associated with HRT changes? Any previous investigations for similar issues?
  • IMB: Timing relative to normal periods (mid-cycle, pre/postmenstrual), duration, amount, relation to intercourse (PCB), regularity of usual cycles, any recent change in pattern.
• Associated Symptoms: Pelvic pain (nature, severity, timing), dyspareunia (superficial vs. deep), vaginal discharge (colour, odour, consistency), urinary symptoms (dysuria, frequency), bowel symptoms (change in habit, rectal bleeding), systemic symptoms (fevers, night sweats, unintentional weight loss – red flags for malignancy).
• Gynaecological History: Cervical screening history (date, result, any previous abnormal smears/colposcopy). Previous gynaecological conditions (fibroids, polyps, endometriosis, PID).
• Obstetric History: Parity (number of pregnancies, live births). Mode of deliveries.
• Contraceptive History (for IMB): Current and past methods, duration of use, any problems. Specifically ask about hormonal methods and IUD/IUS.
• Sexual History (for IMB/PCB, sensitively): Number of partners, new partners, history of STIs.
• Medical History: Known risk factors for endometrial cancer (see previous section). Bleeding disorders (personal/family history of easy bruising/prolonged bleeding). Thyroid disease. Diabetes. Hypertension.
• Medication History: HRT (type, dose, duration, cyclical/continuous, route), tamoxifen, anticoagulants (warfarin, DOACs), antiplatelets, hormonal contraception, any recent changes.
• Family History: Endometrial, ovarian, breast, or colorectal cancer (especially at young ages – consider Lynch Syndrome).
• Social History: Smoking (cervical cancer risk), alcohol, recreational drug use. Occupation/stress levels (can affect cycles).
• Patient’s Ideas, Concerns, and Expectations (ICE): Especially important for PMB where cancer anxiety is high.

Thorough Physical Examination (Chaperone Essential):

1. General Examination: Overall appearance, BMI, signs of anaemia (pallor, conjunctivae), thyroid (goitre, tremor), signs of androgen excess (hirsutism, acne – relevant for PCOS/IMB), lymphadenopathy (inguinal, supraclavicular).
2. Abdominal Examination: Inspect (distension, scars, striae), Palpate (tenderness, masses – uterine, adnexal, ascites), Percuss (for ascites, organomegaly), Auscultate (bowel sounds – less critical for PMB/IMB unless acute pain).
3. Pelvic Examination (ensure patient comfort, clear explanation, chaperone):
   • External Genitalia: Inspect vulva and perineum for lesions, ulcers, atrophy, discharge, signs of trauma.
   • Speculum Examination (Cusco’s speculum):
     • Inspect vaginal walls: Colour, rugosity (atrophy = pale, smooth), lesions, discharge (collect swabs if indicated – see below).
     • Visualise cervix: Identify os. Note size, shape, surface (smooth, irregular, polyp, erosion, ectropion, suspicious lesion – friable, bleeding on contact, ulcerated). Observe for active bleeding and its origin (cervical os implies uterine source).
     • Perform cervical smear if due or cervix looks suspicious (even if screening up-to-date).
   • Bimanual Examination (lubricated gloved fingers):
     • Assess cervix: Position, consistency, mobility, cervical motion tenderness (CMT – suggests PID).
     • Assess uterus: Size (normal, bulky e.g. fibroids/adenomyosis), shape/contour (irregular with fibroids), position (ante/retroverted), mobility (fixed suggests malignancy/endometriosis), tenderness.
     • Assess adnexa (ovaries and fallopian tubes): Palpate for masses, tenderness. Normal ovaries are often not palpable, especially postmenopausally.
     • Assess fornices and parametrium for tenderness or induration.
   • Rectovaginal examination: Rarely needed for initial PMB/IMB assessment unless specific concerns like suspected rectovaginal endometriosis or advanced cervical/rectal cancer.

Strategic Investigations:

Initial Investigations (Bedside/Clinic):

• Urine Pregnancy Test (β-hCG): Essential for ALL reproductive-aged women with IMB or unexplained pelvic symptoms.
• Urine Dipstick: For haematuria (alternative source of “bleeding”), proteinuria, nitrates/leukocytes (UTI).
• Swabs (if indicated by history/examination):
  • High Vaginal Swab (HVS): For microscopy, culture & sensitivity (BV, Candida, Trichomonas).
  • Endocervical Swabs: For NAAT (Chlamydia, Gonorrhoea) if cervicitis or PID suspected, or risk factors for STI.
• Cervical Smear/HPV test: If due according to national screening programme, or if cervix looks abnormal. This is a screening test, not a primary diagnostic test for symptomatic bleeding, but important not to miss opportunity.

Blood Tests (based on clinical suspicion):

• Full Blood Count (FBC): To assess for anaemia due to chronic or acute blood loss. Check haemoglobin, MCV.
• Coagulation Screen (PT, APTT, Fibrinogen): If personal/family history of bleeding diathesis or very heavy bleeding.
• Thyroid Function Tests (TSH, Free T4): If symptoms suggest thyroid dysfunction (can cause menstrual irregularity).
• Serum FSH, LH, Oestradiol: May be useful in IMB if suspecting premature ovarian insufficiency or specific ovulatory disorders (less routine, more specialist). For PMB, these confirm menopausal status but are not needed if clinically obvious.
• CA-125: NOT a routine test for PMB or IMB. May be considered if adnexal mass found on TVUS or high suspicion of ovarian cancer, but it has low specificity for endometrial cancer.

Imaging & Endometrial Assessment (Key for PMB and selected IMB):

1. Transvaginal Ultrasound (TVUS): First-line imaging for PMB and most IMB cases needing structural assessment.

• Endometrial Thickness (ET):
  • PMB (NICE NG12):
    • Women NOT on HRT: ET < 4mm is generally reassuring (low risk of cancer). If bleeding settles, may observe. If persists, biopsy considered. (Some local guidelines may use <5mm).
    • ET ≥ 4mm (or thickened/irregular appearance, or fluid in cavity): Requires endometrial biopsy.
  • PMB (Women ON HRT/Tamoxifen): ET cut-offs are less reliable.
    • Sequential HRT: ET varies with cycle phase. Bleeding should be predictable withdrawal bleed. Unscheduled bleeding warrants biopsy.
    • Continuous Combined HRT: Endometrium should remain thin (ideally <5mm). Any unscheduled/persistent bleeding warrants biopsy, even if ET <5mm.
    • Tamoxifen: Often causes thickened/cystic endometrium. Bleeding always warrants biopsy.
  • IMB: No strict ET cut-off, but a significantly thickened or irregular endometrium (e.g., >12-16mm in reproductive age, or >5mm in perimenopausal/older women with risk factors) may warrant biopsy, especially if persistent IMB or other risk factors for endometrial pathology.
• Other TVUS Findings:
  • Assess uterine size, shape, myometrial texture (fibroids – size, number, location especially submucosal; adenomyosis – bulky, heterogeneous myometrium).
  • Identify endometrial polyps (focal, well-defined intracavitary lesion).
  • Assess adnexa for ovarian cysts/masses.
  • Presence of free fluid in pelvis.

2. Endometrial Sampling (Biopsy): To obtain histology.

• Outpatient Pipelle Biopsy:
  • First-line method for endometrial sampling in most cases.
  • Thin, flexible catheter inserted through cervix into uterine cavity. Suction applied to aspirate endometrial tissue.
  • Performed in outpatient clinic, usually without anaesthesia (can cause cramping).
  • Good sensitivity for diffuse endometrial cancer/hyperplasia. May miss focal lesions (e.g., small polyps, focal cancer).
  • Not always successful (cervical stenosis, patient discomfort).
• Hysteroscopy + Directed Biopsy / Polypectomy / Dilatation & Curettage (D&C):
  • Gold standard for endometrial assessment. Allows direct visualisation of the endometrial cavity using a hysteroscope (thin telescope).
  • Can be done as outpatient procedure (Office Hysteroscopy) or under general/regional anaesthesia (Day Case Hysteroscopy).
  • Indications:
    • Failed/inadequate Pipelle biopsy.
    • Persistent PMB/IMB despite “normal” Pipelle (if high suspicion remains).
    • Focal lesion (e.g., polyp, submucosal fibroid) seen on TVUS requiring direct visualisation and targeted biopsy/removal.
    • Thickened ET where Pipelle is negative but suspicion remains.
    • Diagnostic uncertainty.
  • Allows for targeted biopsies of suspicious areas and therapeutic procedures like polypectomy or removal of small submucosal fibroids.
  • D&C (often done with hysteroscopy) involves dilating the cervix and curetting the endometrial lining; less commonly performed alone now due to superiority of hysteroscopy for diagnosis.

Holistic Management, OSCE Strategies & CBD Focus

Management Principles: Tailored to Cause & Patient

Management is dictated by the underlying diagnosis, patient’s age, symptoms, fertility desires (for IMB), comorbidities, and preferences. All suspected/confirmed cancers are discussed at a Gynae-Oncology Multidisciplinary Team (MDT) meeting.

Management of Postmenopausal Bleeding (PMB):

• Endometrial Cancer:
  • Standard treatment is Total Hysterectomy and Bilateral Salpingo-oophorectomy (THBSO). Often performed laparoscopically or robotically.
  • May involve staging with lymph node assessment (pelvic +/- para-aortic lymphadenectomy) depending on grade and depth of myometrial invasion.
  • Adjuvant therapy (radiotherapy, chemotherapy, hormone therapy) depends on final histology (stage, grade, lymphovascular space invasion).
  • In frail elderly patients unfit for surgery, primary radiotherapy or progestogen therapy may be considered.
• Endometrial Hyperplasia:
  • Hyperplasia WITHOUT Atypia:
    • Low risk of progression to cancer (~1-3%).
    • Treatment: High-dose progestogens to induce endometrial regression.
      • Levonorgestrel-releasing Intrauterine System (LNG-IUS / Mirena coil): First-line, highly effective, provides contraception if needed. Left in situ for 5 years.
      • Continuous oral progestogens (e.g., Medroxyprogesterone acetate, Norethisterone).
    • Follow-up endometrial biopsies (e.g., at 6 months) to confirm regression.
    • Hysterectomy if progestogen therapy fails, patient declines/intolerant to progestogens, or completed family and prefers definitive treatment.
  • Atypical Hyperplasia (Endometrial Intraepithelial Neoplasia – EIN):
    • High risk of progression to cancer (~30-40% may have co-existent cancer).
    • Treatment: THBSO is the recommended treatment.
    • If patient desires fertility preservation or is unfit for surgery: Long-term high-dose progestogens (LNG-IUS or oral) with very close surveillance (frequent biopsies, hysteroscopy). Requires detailed counselling about risks.
• Endometrial Polyps:
  • Hysteroscopic polypectomy (removal via hysteroscope) is standard, especially if symptomatic, large (>1.5cm), or patient has risk factors for malignancy. Histology of polyp is essential.
  • Small, asymptomatic polyps in low-risk individuals may sometimes be observed.
• Atrophic Vaginitis/Endometritis:
  • If biopsy confirms atrophy and excludes malignancy/hyperplasia:
    • Topical vaginal oestrogen (creams, pessaries, Estring ring): Low dose, acts locally, minimal systemic absorption. Very effective for symptoms of vaginal dryness, dyspareunia, and atrophic bleeding.
    • Reassurance if bleeding resolves.
• HRT-Related Bleeding:
  • Ensure adequate investigation to exclude other pathology first.
  • May involve adjusting HRT type or dose (e.g., ensuring adequate progestogen component if on oestrogen with a uterus, changing from cyclical to continuous combined or vice versa, or altering delivery route). This should be guided by a specialist if bleeding is problematic.
• No Pathology Found (after thorough investigation): Reassurance, safety netting to return if bleeding recurs. Consider atrophic changes as likely cause if other pathology excluded.

Management of Intermenstrual Bleeding (IMB):

Target underlying cause, consider fertility wishes, symptom severity.

• Pregnancy-Related: Managed according to specific diagnosis (e.g., expectant/medical/surgical for miscarriage; methotrexate/surgery for ectopic).
• Hormonal/Contraceptive-Related:
  • COCP Breakthrough Bleeding: Reassurance (often settles in 3 months). Check compliance. Consider pill with higher oestrogen dose or different progestogen if persistent.
  • Progestogen-Only Methods: Reassurance about commonality of irregular bleeding. Can try short course of NSAIDs or oestrogen (unlicensed). If intolerable, change method. LNG-IUS (Mirena) often improves bleeding pattern over time.
• Ovulatory Dysfunction (e.g., PCOS, perimenopause):
  • Lifestyle modification (weight management for PCOS).
  • For cycle regulation & endometrial protection (if anovulatory):
    • LNG-IUS (Mirena).
    • COCP (if no contraindications).
    • Cyclical oral progestogens (e.g., Medroxyprogesterone acetate 10mg for 12-14 days each month).
• Structural Lesions:
  • Cervical Ectropion: Reassurance if asymptomatic. If problematic PCB, consider cryotherapy or silver nitrate (less common now).
  • Cervical/Endometrial Polyps: Polypectomy (hysteroscopic for endometrial, often outpatient for cervical).
  • Fibroids: Management depends on size, location, symptoms, fertility.
    • Medical: Tranexamic acid, Mefenamic acid, hormonal (LNG-IUS, COCP, GnRH analogues – temporary, Ulipristal acetate – specific criteria).
    • Surgical: Myomectomy, Hysteroscopic resection of submucosal fibroids, Uterine Artery Embolization (UAE), Hysterectomy.
  • Adenomyosis: LNG-IUS, COCP, GnRH analogues, Hysterectomy.
• Infections (Cervicitis, PID): Appropriate antibiotics for patient and partners. PID may require inpatient treatment.
• Dysfunctional Uterine Bleeding (DUB) / Abnormal Uterine Bleeding – Ovulatory (AUB-O) / Not Otherwise Specified (AUB-N): When no specific pathology is found and ovulation is occurring.
  • Medical (Treatment Ladder – NICE NG88 for Heavy Menstrual Bleeding, principles apply for problematic IMB):
    1. LNG-IUS (Mirena): Often first-line if long-term contraception also desired/acceptable.
    2. Tranexamic Acid (antifibrinolytic, taken during bleeding).
    3. NSAIDs (e.g., Mefenamic acid, taken during bleeding).
    4. Combined Oral Contraceptives (COCP).
    5. Cyclical Oral Progestogens (e.g., Norethisterone 5mg TDS during bleeding for acute control, or cyclical for regulation).
  • Surgical (if medical fails/contraindicated/not desired): Endometrial ablation (for women who have completed family), Hysterectomy (definitive).

OSCE Focus: Excelling in PMB/IMB Stations

These stations often test history taking, communication (explaining investigations, results, management plans), risk assessment, and professionalism.

1. Preparation is Key: Know your definitions, risk factors for endometrial cancer, and the NICE guidelines for PMB investigation pathway cold.
2. Introduction (WIPER): Wash hands (or state), Introduce self & role, Patient ID (name, DOB), Explain purpose of consultation, gain Consent, Ensure privacy & Respect (offer chaperone proactively for any examination).
3. Empathetic History Taking:
   • Use a structured approach (e.g., SOCRATES for bleeding, specific questions for PMB/IMB from section 3).
   • Actively listen, use verbal nods (“I see,” “Okay”), show empathy (“I understand this must be worrying for you”).
   • Thoroughly explore red flag symptoms and risk factors (especially for PMB).
   • Actively explore Ideas, Concerns, and Expectations (ICE). For PMB, the biggest concern is usually cancer – address this sensitively. “What are your main worries about this bleeding?” “What were you hoping we could do for you today?”
4. Explaining Investigations Clearly:
   • Use simple, jargon-free language. Check understanding.
     • TVUS: “It’s an internal ultrasound scan, like the one some women have in early pregnancy. A small probe is gently placed into the vagina to get a clear picture of the lining of your womb and your ovaries. It can be a bit uncomfortable but shouldn’t be painful. It helps us measure the thickness of the womb lining.”
     • Pipelle Biopsy: “If the lining looks thickened, we may need to take a small sample from it. This is usually done in the clinic. A very thin tube, like a straw, is passed through the neck of the womb to get a tiny piece of the lining. It can cause some period-like cramping, but it’s usually over quickly.”
     • Hysteroscopy: “This is a procedure where we use a small telescope with a camera to look directly inside your womb. We can see the lining clearly and take samples (biopsies) if needed, or remove things like polyps. It can sometimes be done in clinic while you’re awake, or with some sedation or a short general anaesthetic.”
   • Always mention that results will be discussed once available.
5. Communicating Results & Management Plans:
   • If breaking bad news (e.g., suspected cancer), use a structured approach (e.g., SPIKES model if it’s a dedicated station – less likely for ST1/2 to deliver definitive cancer diagnosis, more likely “suspicious findings needing further tests”).
     • Setting, Perception, Invitation, Knowledge, Empathy, Strategy/Summary.
   • Discuss management options, pros and cons, involve the patient in decision-making. “There are a few ways we can approach this…”
   • Provide clear safety netting: “If the bleeding gets much heavier, or you develop severe pain, or feel unwell, please contact your GP or attend A&E.” “We will arrange follow-up to discuss results/progress.”
6. Professionalism: Maintain a calm, confident, respectful, and empathetic manner. Ensure patient dignity is maintained (e.g., offering a sheet for examination).
7. Structure & Timing: Manage your time effectively. Have a clear structure for the consultation. Summarise at key points and at the end.

Hone your communication and clinical reasoning for OSCEs with The MDT’s resources, including our interactive OSCEbot for simulated practice.

Case-Based Discussion (CBD) Focus: PMB/IMB

Flashcards: PMB & IMB Core Knowledge

Click on each card to reveal the answer. Reinforce your learning!

Aetiology and Classification of Amenorrhoea

Causes are diverse and classified based on primary vs. secondary presentation, and the level of HPO axis disruption.

Primary Amenorrhoea: Key Causes

Secondary Amenorrhoea: Common and Important Causes

Comprehensive History Taking for Amenorrhoea

A meticulous history is the cornerstone of diagnosing amenorrhoea. It guides examination and investigations.

Key Areas to Cover:

• Menstrual History:
  • Primary vs. Secondary: Age of menarche (if any). If secondary, LMP date, previous cycle pattern (regularity, length, flow, duration, associated pain/dysmenorrhoea). Any recent changes?
  • Post-coital or intermenstrual bleeding (could suggest cervical pathology).
• Symptoms of Pregnancy: Nausea, vomiting, breast tenderness, urinary frequency, fatigue. (Crucial for secondary amenorrhoea).
• Symptoms of Oestrogen Deficiency:
  • Vasomotor: Hot flushes, night sweats.
  • Urogenital: Vaginal dryness, dyspareunia, recurrent UTIs.
  • Psychological: Mood swings, irritability, poor concentration, sleep disturbance.
  • Musculoskeletal: Joint pains, increased fracture risk (long-term).
• Symptoms of Hyperandrogenism:
  • Hirsutism (excess terminal hair in male pattern): Onset, progression, severity (ask about specific areas like face, chest, back).
  • Acne: Severity, persistence beyond adolescence.
  • Androgenic alopecia (male-pattern hair loss).
  • Deepening of voice, clitoromegaly (signs of significant virilisation – RED FLAG for androgen-secreting tumour).
• Symptoms Suggestive of Pituitary/CNS Pathology:
  • Galactorrhoea (milky nipple discharge – spontaneous or on expression).
  • Headaches (character, severity, location, associated features like visual changes).
  • Visual disturbances (blurred vision, diplopia, bitemporal hemianopia – suggests optic chiasm compression).
  • Anosmia/hyposmia (loss/reduction of smell – think Kallmann syndrome).
• Symptoms Suggestive of Thyroid Dysfunction:
  • Hypothyroidism: Fatigue, weight gain, constipation, cold intolerance, dry skin, hair loss.
  • Hyperthyroidism: Weight loss, palpitations, anxiety, heat intolerance, tremor, diarrhoea.
• Weight & Lifestyle:
  • Recent significant weight loss or gain (quantify). History of eating disorders (anorexia, bulimia, EDNOS) – ask sensitively.
  • Dietary habits (restrictive diets, veganism without supplementation).
  • Exercise regimen: Type, intensity, frequency, duration. Any recent significant increase?
  • Stress levels: Home, work, personal life. Major life events.
• Past Gynaecological & Obstetric History:
  • Previous pregnancies: Outcomes, mode of delivery, complications (e.g., PPH for Sheehan’s).
  • Dilatation and Curettage (D&C) or other uterine surgery/instrumentation (risk for Asherman’s).
  • History of PID, STIs. Cervical smear history.
  • Previous gynaecological conditions (e.g., endometriosis, fibroids).
• Past Medical History:
  • Chronic illnesses: Diabetes, renal disease, liver disease, autoimmune conditions (e.g., Addison’s, autoimmune oophoritis).
  • Cancer history: Chemotherapy, radiotherapy (especially pelvic/cranial).
  • Previous surgery, particularly pelvic or cranial.
  • Head injury.
• Drug History: Current and recent medications (prescription, over-the-counter, herbal). Specifically ask about:
  • Hormonal contraceptives (type, duration of use, when stopped).
  • Antipsychotics, antidepressants (especially TCAs, SSRIs).
  • Anti-emetics (metoclopramide, domperidone).
  • Opiates, antihypertensives (methyldopa).
  • GnRH analogues, chemotherapy drugs.
• Family History:
  • Menstrual disorders in mother/sisters (e.g., POI, PCOS).
  • Age of maternal menopause.
  • Genetic conditions (Turner’s, Kallmann’s, Fragile X).
  • Thyroid disorders, diabetes, autoimmune conditions.
• Developmental History (Crucial for Primary Amenorrhoea):
  • Milestones of pubertal development: Thelarche (breast development – age?), pubarche (pubic hair – age?), adrenarche. Sequence of events.
  • Growth spurts. Comparison with peers.
• Social History: Smoking, alcohol intake, recreational drug use. Occupation and impact of symptoms. Support systems. Fertility desires.

Focused Clinical Examination for Amenorrhoea

The examination aims to identify signs related to the potential causes identified in the history. Always ensure chaperone, consent, privacy, and explain each step.

1. General Examination:

• Appearance & Build: Well/unwell, nutritional status (cachectic, obese), syndromic features (e.g., Turner’s).
• Vital Signs: Blood pressure (PCOS, Cushing’s), pulse, temperature.
• Anthropometry:
  • Height & Weight: Calculate BMI (kg/m²).

    (BMI Interpretation)

    Low BMI (<18.5) suggests FHA. High BMI (>25 overweight, >30 obese) associated with PCOS, insulin resistance.
  • Waist circumference: (If BMI elevated) >80cm in women indicates increased metabolic risk.
  • Arm span vs. Height: (If suspecting eunuchoid proportions or specific syndromes).

2. Assessment of Secondary Sexual Characteristics (Tanner Staging):

3. Specific Signs to Look For:

• Skin:
  • Hirsutism: Assess distribution and severity using Ferriman-Gallwey score if possible (verbalise in OSCE). Note areas like face, chin, upper lip, chest, abdomen, back, inner thighs.

    (Ferriman-Gallwey Score Basics)

    Scores 9 body areas (0-4) for terminal hair growth. Total score >8 often indicates hirsutism. In OSCE, describe the pattern and areas affected.
  • Acne, oily skin (hyperandrogenism).
  • Acanthosis nigricans: Velvety, hyperpigmented plaques in skin folds (axillae, neck, groin) – sign of insulin resistance (PCOS, obesity).
  • Striae: Purple/violaceous striae (Cushing’s), pale striae (weight changes).
  • Pallor (anaemia, chronic disease), dry skin (hypothyroidism), bruising (Cushing’s).
  • Signs of virilisation (RED FLAGS): Clitoromegaly, deep voice, temporal balding, increased muscle mass. Suggests very high androgen levels (e.g., androgen-secreting tumour).
• Head & Neck:
  • Thyroid gland: Inspect and palpate for goitre, nodules.
  • Eyes: Exophthalmos (hyperthyroidism). Visual fields by confrontation (if suspecting pituitary tumour compressing optic chiasm – bitemporal hemianopia).
  • Sense of smell: Briefly test with non-irritant substance if Kallmann’s suspected.
  • Oral cavity: Dental erosions (bulimia).
• Chest:
  • Inspect breast development (Tanner stage).
  • Check for galactorrhoea: Ask patient to attempt expression or, if appropriate and with consent, gently attempt (not routine in OSCE unless strong history).
• Abdominal Examination:
  • Inspect for distension, striae, surgical scars.
  • Palpate for masses (ovarian, uterine – though rarely cause amenorrhoea directly unless very large or hormonally active), hepatosplenomegaly.
  • Check for ascites (rarely, Meigs’ syndrome).

4. Pelvic Examination (Perform or describe as per OSCE instructions):

Always with chaperone, consent, explain procedure, ensure privacy and comfort.

• Inspection of External Genitalia:
  • Pubic hair distribution (Tanner stage).
  • Clitoral size (normal <1cm in length, <0.5cm in width). Clitoromegaly?
  • Labia, perineum, urethral meatus. Signs of oestrogen deficiency (atrophy, pallor, dryness).
  • Hymen: Patent, imperforate, microperforate. Any bulging?
• Speculum Examination:
  • Vagina: Length, patency, presence of septa. Mucosal appearance (rugae, colour, moisture – atrophic changes if oestrogen deficient). Any discharge?
  • Cervix: Appearance, presence, size. Any lesions, polyps, discharge? Cervical stenosis? (Unable to pass a small dilator if attempted).
• Bimanual Examination:
  • Uterus: Presence (crucial for primary amenorrhoea – MRKH, AIS), size, shape, consistency, mobility, tenderness. Anteverted/retroverted.
  • Adnexa (Ovaries & Fallopian Tubes): Palpate for masses, tenderness. Ovaries may not be palpable in postmenopausal women or if BMI high. Polycystic ovaries are usually not palpable unless very enlarged.
  • Assess for any pelvic masses or tenderness.

Investigations and Diagnostic Algorithm for Amenorrhoea

Investigations are guided by the history and examination, following a stepwise approach to confirm or exclude potential diagnoses efficiently.

Initial (First-Line) Investigations for All Cases of Amenorrhoea (after clinical assessment):

1. Pregnancy Test (β-hCG): URINE or SERUM. Mandatory first step for secondary amenorrhoea, and often done in primary amenorrhoea if sexually active or to rule out rare cryptic pregnancies.
2. Follicle-Stimulating Hormone (FSH) & Luteinizing Hormone (LH):

   (FSH/LH Interpretation – Click for Details)

   • High FSH (>20-25 IU/L, often >40 IU/L on repeat): Suggests ovarian insufficiency (hypergonadotropic hypogonadism). E.g., POI, Turner syndrome. LH also usually high.
   • Low/Normal FSH & LH: Suggests hypothalamic/pituitary cause (hypogonadotropic hypogonadism) OR eugonadotropic anovulation (like PCOS). E.g., FHA, Kallmann’s, pituitary tumour, PCOS (LH may be disproportionately high relative to FSH).
   • LH:FSH Ratio: An LH:FSH ratio >2:1 or >3:1 can be suggestive of PCOS, but is not diagnostic alone and not consistently present.
3. Thyroid Stimulating Hormone (TSH) & Free T4 (fT4): To screen for thyroid dysfunction (both hypo- and hyperthyroidism).
4. Prolactin: To screen for hyperprolactinaemia.

   (Prolactin Interpretation – Click for Details)

   • Mild elevation: Can be due to stress, venepuncture, recent meal, medications, subclinical hypothyroidism. Repeat fasting, non-stressed sample.
   • Moderate-High elevation: Suspect prolactinoma, significant drug effect. Macroprolactin should be excluded if assays differ.
   • If prolactin is high, and TSH is also high, treat hypothyroidism first, then recheck prolactin.
5. Oestradiol (E2): Helps interpret FSH/LH. Low E2 with high FSH confirms ovarian failure. Low E2 with low/normal FSH confirms hypothalamic/pituitary hypogonadism or outflow tract issue with ovarian quiescence. Normal/high E2 with amenorrhoea suggests anovulation (PCOS) or outflow tract obstruction with functioning ovaries.

Second-Line Investigations (Guided by initial results and clinical picture):

• Pelvic Ultrasound Scan (Transvaginal preferred if sexually active and acceptable; transabdominal otherwise):

  (Pelvic USS Indications & Findings – Click)

  • Uterus: Presence/absence (MRKH, AIS), size, shape, congenital anomalies (e.g., bicornuate). Endometrial thickness (thin in hypo-oestrogenic states or Asherman’s; thick in anovulatory states like PCOS or if oestrogen unopposed).
  • Ovaries: Presence, size, volume, follicular count (for PCO morphology: ≥12 follicles 2-9mm OR ovarian volume >10ml). Presence of cysts, tumours.
  • Outflow Tract: Look for haematocolpos/haematometra if obstruction suspected.
  • Essential in primary amenorrhoea and very useful in secondary.
• Androgen Profile (if signs of hyperandrogenism or PCOS suspected):
  • Total Testosterone.
  • Sex Hormone Binding Globulin (SHBG) – to calculate Free Androgen Index (FAI = Total Testosterone / SHBG x 100).
  • Consider DHEAS (adrenal androgen) and 17-hydroxyprogesterone (for congenital adrenal hyperplasia – CAH, especially late-onset) if virilisation is severe or rapid, or if testosterone is very high.
• Karyotyping:
  • Indicated in primary amenorrhoea, especially if short stature (Turner’s 45,XO) or high FSH.
  • Indicated if Androgen Insensitivity Syndrome (AIS) suspected (will show 46,XY).
  • Consider in POI if <30 years old.
• Progesterone Challenge Test: (Less common now, but tests oestrogen status and outflow tract patency).

  (Progesterone Challenge – Click)

  Administer oral progestogen (e.g., medroxyprogesterone acetate 10mg daily for 5-10 days).

  • Withdrawal bleed occurs: Indicates adequate endogenous oestrogen priming of endometrium and a patent outflow tract. Suggests anovulation (e.g., PCOS, mild hypothalamic dysfunction).
  • No withdrawal bleed: Suggests either (1) Hypo-oestrogenism (HPO axis failure or severe dysfunction) OR (2) Outflow tract obstruction (e.g., Asherman’s, cervical stenosis) OR (3) Endometrial non-responsiveness.

  To differentiate these, an oestrogen + progesterone challenge can be done. If bleed occurs, confirms outflow tract patency and points to hypo-oestrogenism. If no bleed, points to outflow tract/endometrial problem.
• Hysteroscopy / Hysterosalpingogram (HSG) / Saline Infusion Sonohysterography (SIS): If Asherman’s syndrome or other intrauterine pathology is suspected (e.g., no bleed on progesterone challenge despite evidence of oestrogen). Hysteroscopy is gold standard for Asherman’s.
• MRI Brain/Pituitary:
  • If significantly elevated prolactin (to look for prolactinoma or other pituitary lesion).
  • If hypogonadotropic hypogonadism (low FSH/LH, low E2) with no obvious cause (e.g., FHA ruled out) to look for pituitary/hypothalamic tumours (e.g., craniopharyngioma), infiltrative disease, or empty sella.
  • If neurological symptoms (headaches, visual changes).
• Bone Mineral Density (DEXA scan): If prolonged hypo-oestrogenism (amenorrhoea >6-12 months with low oestrogen, e.g., FHA, POI) to assess for osteopenia/osteoporosis.
• Specific tests for Cushing’s (e.g., 24hr urinary free cortisol, low-dose dexamethasone suppression test) or CAH (early morning 17-OHP) if clinically suspected.
• Fragile X (FMR1) premutation testing: In women with POI, especially if family history of intellectual disability or POI.

Simplified Diagnostic Algorithm (Conceptual Flow):

Management Principles for Amenorrhoea

Management is highly dependent on the underlying cause, the patient’s symptoms, and their fertility desires. It often involves a multidisciplinary team.

General Principles:

• Treat the Underlying Cause: This is paramount.
• Address Symptoms: E.g., oestrogen deficiency, hyperandrogenism.
• Manage Complications: E.g., infertility, osteoporosis, cardiovascular risk, endometrial hyperplasia.
• Patient Education and Counselling: Explain the diagnosis, implications, and management options. Address psychosocial impact.
• Fertility Considerations: Discuss options if fertility is desired.
• Multidisciplinary Approach: May involve gynaecologists, endocrinologists, dietitians, psychologists, fertility specialists.

Specific Management Examples:

OSCE & Communication Skills for Amenorrhoea

Amenorrhoea stations frequently assess communication, empathy, structured history taking, examination technique (or description), and your ability to formulate a differential diagnosis, investigation, and management plan.

Core OSCE Approach (WIPER +):

1. Wash hands (or state you would).
2. Introduce yourself (name, role), confirm Patient identity (name, DOB).
3. Explain purpose of consultation, obtain consent, ensure Respect and privacy. Ask about chaperone.
4. Build Rapport: Open questions (“How can I help you today?”), active listening, empathetic responses (“I can see this is concerning for you.”).

History Taking in OSCEs:

• Be systematic, cover all key areas (as detailed in History section).
• Use a mix of open and closed questions appropriately.
• Signpost: “Now I’d like to ask some questions about…”
• Pick up on cues (verbal and non-verbal).
• Summarise periodically to check understanding and show you’re processing information.
• Specifically ask about RED FLAGS: rapid/severe virilisation, neurological symptoms, significant unexplained weight loss, symptoms of malignancy.

Examination in OSCEs:

• If performing: Explain each step, ask for consent for sensitive parts, ensure comfort and dignity. Verbalise findings clearly.
• If describing: Be precise. “I would perform a general examination looking for…, followed by a focused examination including assessment of secondary sexual characteristics using Tanner staging, signs of hyperandrogenism like hirsutism using the Ferriman-Gallwey score, and thyroid examination. If appropriate and with consent, a pelvic examination would be conducted to assess…”

Presenting Differentials & Investigations:

• “Based on your symptoms of [key symptom 1] and [key symptom 2], my main initial thoughts are [Differential 1] or [Differential 2]. To help clarify this, I would suggest some initial tests.”
• Justify each investigation: “A pregnancy test is essential first. Then, blood tests for FSH, LH, TSH, and prolactin will help us understand how your hormones are working.”

Discussing Management & Counselling:

• Explain findings clearly, avoiding jargon. Use diagrams if helpful/available.
• Discuss management options based on likely/confirmed diagnosis.
• Involve the patient: “What are your thoughts on this?” “Do you have particular concerns or preferences regarding treatment?”
• Address fertility concerns proactively and sensitively.
• Offer patient information leaflets and support group details.
• Arrange follow-up.

Case-Based Discussion (CBD) Approach to Amenorrhoea

CBDs assess your clinical reasoning, decision-making, and application of knowledge in the context of a real (or simulated) case. Amenorrhoea is a common topic.

Preparing for an Amenorrhoea CBD:

• Know Your Case: Thoroughly review the patient’s history, examination findings, investigation results, and management plan. Understand the timeline.
• Anticipate Questions: Think about what aspects of the case might be queried (differentials, investigation choices, management rationale, ethical issues).
• Core Knowledge: Refresh your understanding of the pathophysiology, causes, and guidelines related to amenorrhoea.

Structure of Presenting an Amenorrhoea Case in a CBD:

1. Brief Summary: “This case is about Ms. [Initials], a [Age]-year-old lady who presented with [primary/secondary] amenorrhoea for [duration].”
2. Key History Points: Relevant positives and negatives from menstrual, gynaecological, medical, drug, family, and social history. Highlight symptoms like galactorrhoea, hirsutism, weight changes, stress.
3. Key Examination Findings: BMI, secondary sexual characteristics, signs of hyperandrogenism, thyroid, pelvic findings (if done).
4. Differential Diagnoses (at presentation): List 2-3 most likely differentials and briefly justify why. “My initial differentials were A, B, and C because…”
5. Investigations Performed & Rationale: “We started with a pregnancy test, which was negative. Initial bloods showed [FSH, LH, Prolactin, TSH results]. A pelvic ultrasound was done because…”
6. Results & Interpretation: Explain what the results mean in the context of the patient.
7. Final Diagnosis & Management Plan: State the working/final diagnosis. Outline the management provided (lifestyle, medical, surgical) and the rationale. Mention any referrals made.
8. Patient’s Perspective & Follow-up: Briefly mention patient engagement, concerns, and follow-up arrangements.

Common CBD Questions for Amenorrhoea Cases:

Example CBD Case Snippet & Discussion Points:

“This case concerns a 22-year-old elite long-distance runner who presented with secondary amenorrhoea for 10 months. Her BMI was 17.8. Initial bloods showed low FSH, LH, and oestradiol. TSH and prolactin were normal. A pregnancy test was negative.”

Potential Discussion Points:

• Likely diagnosis: Functional Hypothalamic Amenorrhoea (FHA).
• Pathophysiology: How low energy availability affects GnRH pulsatility.
• Further investigations: DEXA scan?
• Management: Lifestyle advice (nutrition, modifying training), role of HRT vs COCP, multidisciplinary team approach (dietitian, sports physician, psychologist).
• Long-term risks: Osteoporosis, infertility.
• Counselling points for the patient.

Flashcards: Amenorrhoea Deep Dive

Click on each card to reveal the answer. Reinforce your knowledge for PLAB/MLA/MSRA!

Eligibility, Risk Assessment & Selection for TOLAC

Thorough assessment is paramount to identify suitable candidates for TOLAC and to provide accurate, individualised counselling.

I. Detailed Obstetric & Medical History:

• Previous Caesarean Section(s):
  • Number: One previous LSCS is the most common scenario. TOLAC after two previous LSCS may be considered in select cases by experienced clinicians in appropriate units, but carries a higher risk of uterine rupture (approx. 1.5-3%). TOLAC after ≥3 CS is generally not recommended.
  • Indication for previous CS: Was it non-recurring (e.g., breech, fetal distress in a non-complicated labour) or recurring (e.g., proven cephalopelvic disproportion, previous failed TOLAC with arrest in second stage despite adequate contractions)? Non-recurring indications favour VBAC success.
  • Type of Uterine Incision (CRUCIAL): Why it Matters

    This is the single most important factor determining uterine rupture risk.

    • Low Transverse (LSCS): Most common, involves the thinner lower uterine segment. Lowest risk of rupture (0.5-0.7% for one). This scar heals well and stretches better during labour.
    • Low Vertical: May be used for preterm breech, anterior placenta praevia. Higher rupture risk than transverse if it extends into the upper segment. Requires careful assessment.
    • Classical (Vertical into upper segment) or T/J-shaped incision: Involves the thicker, more muscular upper segment. Highest risk of rupture (4-9%). These scars do not heal as well and are less able to withstand contractions. TOLAC is contraindicated.

    Pathophysiology: The upper uterine segment is contractile, while the lower segment is relatively passive and distensible during labour. A scar in the contractile portion is under greater stress.

    Action: ALWAYS try to obtain previous operative notes. If unavailable, and scar type is uncertain, counsel about increased risk/uncertainty and generally err on the side of caution (ERCS).

  • Complications of previous CS: e.g., infection, tear extension, uterine atony, need for transfusion.
• Previous Vaginal Births: A history of ANY previous vaginal birth (before or after a CS) significantly increases VBAC success rates (>85-90%) and is reassuring. A previous successful VBAC is particularly favourable.
• Inter-delivery Interval: Generally, >18 months is preferred. Intervals <12-18 months may be associated with a slightly increased risk of uterine rupture (incomplete scar healing).
• Current Pregnancy Factors:
  • Gestational Age: TOLAC typically offered up to 41 weeks. Post-term pregnancy (>41 weeks) can slightly reduce success and may increase IOL need.
  • Estimated Fetal Weight (EFW): Suspected macrosomia (e.g., EFW >4.0-4.5kg) is associated with lower VBAC success and potentially higher rupture risk, especially if previous CS was for dystocia. No absolute cut-off, individualised discussion.
  • Fetal Presentation: Cephalic presentation is essential. Breech or transverse lie are contraindications for TOLAC.
  • Placental Location: Placenta praevia (covering or near os) is a contraindication to vaginal birth, thus TOLAC.
  • Multiple pregnancy (e.g., twins): Can be considered in specific circumstances (e.g., first twin cephalic, after one LSCS) by experienced teams, but generally higher risk.
• Maternal Factors:
  • Age: Advanced maternal age (>35-40) may slightly reduce success.
  • BMI: High BMI (>30 or >35) associated with lower VBAC success and increased operative risks if CS needed.
  • Co-morbidities: e.g., diabetes, hypertension, cardiac disease – need individual assessment.
  • Previous uterine surgery other than CS: e.g., myomectomy (especially if uterine cavity breached), hysteroscopy with significant resection – may be contraindications.

II. Contraindications & Relative Cautions for TOLAC:

III. Predicting VBAC Success:

• Various scoring systems exist (e.g., RCOG VBAC score, ACOG VBAC calculator) to help estimate success but should not be used in isolation. They consider factors like prior vaginal birth, BMI, age, indication for prior CS.
• Key Exam Phrase: “While scoring tools can give us an idea, your individual circumstances and preferences are most important in making this decision together.”

IV. Role of Ultrasound in VBAC Assessment:

• Standard fetal biometry, EFW, presentation, and placental localization.
• Lower Uterine Segment (LUS) Thickness:
  • Measurement by transvaginal or transabdominal ultrasound late in pregnancy.
  • Some studies suggest a very thin LUS (<2.0-2.5mm) may be associated with increased rupture risk.
  • Current status: Not routinely recommended in most guidelines (e.g., RCOG, ACOG) for predicting rupture due to lack of standardization, inter/intra-observer variability, and uncertain predictive value. May have a role in research settings or highly selected cases.
  • Key Exam Phrase: “Currently, measuring the thickness of the scar by ultrasound isn’t routinely done to predict if VBAC is safe, as the evidence isn’t strong enough to guide decisions reliably for everyone.”

Counselling, Shared Decision-Making (SDM) & Management Plan

This is the core of VBAC care, focusing on enabling the woman to make an informed choice.

I. The Counselling Process:

• Timing: Ideally, start discussions in the antenatal period (e.g., around 28-32 weeks, or earlier if complex), allowing time for reflection. Revisit closer to term.
• Environment: Private, unhurried, supportive. Involve partner if woman wishes.
• Use of Decision Aids: Patient information leaflets (e.g., RCOG), online tools can supplement discussion.
• Address ICE:
  • Ideas: “What are your thoughts about giving birth this time?” “What have you heard about VBAC?”
  • Concerns: “What are your main worries or concerns about attempting a vaginal birth, or about having another caesarean?”
  • Expectations: “What are you hoping for from this birth experience?”
• Key Exam Phrase: “My role today is to provide you with information about your options, discuss the benefits and risks for you specifically, and help you make a decision that feels right for you.”

II. Discussing Options: TOLAC vs. ERCS – A Balanced View

Provide absolute numbers and rates where possible (e.g., 1 in 200 risk of rupture vs. “small risk”).

III. Intrapartum Management for TOLAC:

• Setting: Consultant-led unit with continuous EFM capability and immediate (within 30 mins, “decision to delivery interval”) access to theatre, obstetric, anaesthetic, neonatal, and blood transfusion services.
• Team: Experienced midwives and obstetricians. Clear communication within MDT.
• Monitoring:
  • Continuous Electronic Fetal Monitoring (EFM): Mandatory from onset of regular contractions or IOL. FHR abnormalities are the most common sign of uterine rupture.
  • Maternal vital signs, pain assessment.
• IV Access & Bloods: Establish IV access. Group & Save essential; crossmatch blood if higher risk.
• Labour Onset:
  • Spontaneous Labour: Preferred. Await up to 41 (or 41+3/41+6 depending on local policy) weeks.
  • Induction of Labour (IOL):
    • Requires careful senior discussion. Increases rupture risk (2-3 fold vs spontaneous).
    • Methods: Mechanical methods (e.g., balloon catheter, amniotomy) generally preferred over pharmacological.
    • Prostaglandins (PGE2, Dinoprostone): Use with extreme caution, often contraindicated or only in very specific circumstances (e.g., very favourable cervix, single previous LSCS) by senior obstetrician. Misoprostol (PGE1) is generally contraindicated.
    • Key Exam Phrase: “If we need to start labour artificially, some methods are safer than others. We generally prefer methods that don’t involve strong hormone-based drugs to reduce stress on your scar.”
  • Augmentation of Labour (with Oxytocin):
    • Use with extreme caution, by experienced staff, under senior guidance.
    • Start at low dose, titrate slowly. Continuous EFM is vital.
    • Higher risk of uterine rupture if labour is augmented.
    • Have a low threshold for discontinuing if concerns or poor progress.
• Pain Relief: Epidural analgesia is not contraindicated and can be beneficial. It does not reliably mask all signs of uterine rupture (FHR changes, maternal tachycardia often still occur).
• Monitoring Labour Progress: Partogram. Be vigilant for slow progress or arrest, especially if previous CS was for dystocia. This may be an early sign of impending rupture or disproportion. Set clear time limits for progress.
• Second Stage: Avoid prolonged active second stage. Consider assisted vaginal birth if appropriate criteria met.

IV. Recognising & Managing Complications During TOLAC:

• Immediate Management of Suspected Uterine Rupture:
  1. Call for HELP (Obstetric emergency/CRASH call): Alert senior obstetrician, anaesthetist, paediatrician, theatre team.
  2. ABCDE approach for mother: Oxygen, IV fluids (crystalloids, consider blood), monitor vitals.
  3. Discontinue any oxytocin.
  4. Prepare for IMMEDIATE LAPAROTOMY & DELIVERY. Time is critical.
  5. Neonatal team to be present for resuscitation.
  6. Surgical repair of uterus if possible; hysterectomy may be required if repair not feasible or uncontrolled bleeding.
• Management of Failed TOLAC / Arrested Labour:
  • Timely decision for CS if labour is not progressing despite adequate contractions (if augmentation used cautiously) or if there are concerns about fetal/maternal well-being.
  • Communicate clearly with the woman and her partner.

V. Postnatal Care:

• After Successful VBAC: Routine postnatal care. Debrief opportunity. Discuss future pregnancies.
• After ERCS or Emergency CS post-TOLAC: Standard post-caesarean care. Ensure good analgesia, VTE prophylaxis. Debriefing is particularly important after a failed TOLAC or emergency CS. Explore her feelings and experience.

OSCE & Case-Based Discussion (CBD) Focus

I. OSCE Station: VBAC Counselling

This station tests your ability to apply knowledge in a patient-centred communication scenario.

1. Preparation: Know RCOG/NICE guidelines. Practice your structure.
2. Introduction (WIPE): Wash hands, Introduce (name, role – ST1/2 doctor), Patient ID (confirm name, DOB), Explain purpose (“discuss your options for birth after your previous caesarean”), obtain Consent. Set agenda: “Is there anything specific you’d like to cover today?”
3. Gather Information (Active Listening):
   • Previous CS: “Could you tell me about your previous caesarean birth? What was the reason for it? How was your recovery?”
   • Current wishes/understanding: “What are your thoughts or feelings about how you’d like to give birth this time?” “What do you already know about VBAC or repeat caesarean?”
   • Address ICE throughout.
4. Provide Information (Balanced & Individualised):
   • Explain TOLAC and ERCS clearly.
   • Give personalised success rates for TOLAC (e.g., “For someone with your history of one previous caesarean for breech, and no other complications, the chance of a successful vaginal birth is around 70-75%”).
   • Use the “Benefits & Risks” framework for both options (as detailed in previous section). Quantify risks (e.g., “The risk of the scar opening, called uterine rupture, is about 1 in 200… this can have serious consequences for you and baby…”).
   • Key Exam Phrase: “It’s important to understand that both options have their own set of benefits and potential downsides, and what’s ‘best’ can be different for different women.”
5. Shared Decision-Making:
   • “What are your initial thoughts on what we’ve discussed?” “How do these options weigh up for you?”
   • Acknowledge her feelings. Validate concerns.
   • Offer patient information leaflets/decision aids.
6. Summarise & Plan:
   • Recap key points and the chosen plan (or plan for further discussion).
   • If TOLAC: Briefly outline intrapartum plan (hospital birth, monitoring, signs of rupture to report).
   • If ERCS: Briefly outline pre-op, procedure, post-op.
   • Document thoroughly. Arrange follow-up if needed.
   • Safety net: “If you have any bleeding, pain, reduced movements, or go into labour before our next appointment, please contact the hospital immediately.”

II. Case-Based Discussion (CBD) Pointers for VBAC:

A CBD allows deeper exploration of your clinical reasoning and knowledge application.

Key Areas to Demonstrate in a VBAC CBD:

• Application of Guidelines: Referencing NICE, RCOG, or local trust guidelines.
• Risk Assessment: How you identify and weigh individual risk factors.
• Shared Decision-Making: How you facilitated this process, documented consent.
• Clinical Reasoning: Justification for management choices (e.g., mode of IOL, timing of CS if TOLAC fails).
• Recognition & Management of Complications: Your understanding of uterine rupture, fetal distress.
• Multidisciplinary Team Working: When and how you involve seniors, midwives, anaesthetists, neonatologists.
• Communication: With patient, family, and team members.
• Reflection & Learning: What you learned, what you might do differently.

Preparing for a VBAC CBD:

• Choose a case you were actively involved in.
• Review the notes thoroughly.
• Re-read relevant guidelines.
• Anticipate questions about alternative management or potential complications.
• Be prepared to discuss the evidence base for your decisions.

The MDT offers comprehensive support for specialty exams, including resources for CBD preparation.

Flashcards: VBAC Rapid Review

Click on each card to reveal the answer. Test your core knowledge!

The MDT provides extensive flashcard libraries. Enhance your revision across all medical specialties for PLAB/MLA/MSRA!

Pathophysiology & Aetiology of Preterm Labour

Preterm labour is a complex syndrome resulting from multiple pathological processes that activate a “final common pathway” leading to uterine contractions, cervical ripening, and membrane rupture.

The Final Common Pathway:

Regardless of the initial trigger, this pathway involves:

• Increased prostaglandin synthesis (PGE2, PGF2α) causing myometrial contractility and cervical ripening.
• Increased expression of contraction-associated proteins (CAPs) like oxytocin receptors and gap junctions.
• Matrix metalloproteinases (MMPs) degrading cervical collagen.
• Inflammatory cytokine cascade (e.g., IL-1β, IL-6, TNF-α).

Major Aetiological Pathways:

Risk Factors & Prevention Strategies for Preterm Labour

Identifying Women at Risk:

A thorough history is key. Risk factors can be broadly categorised:

Prevention Strategies:

Focus on identifying high-risk women and offering targeted interventions.

Diagnosis & Initial Assessment in Suspected Preterm Labour

Prompt and accurate assessment is crucial. The goal is to confirm PTL, assess maternal/fetal well-being, and determine appropriate management.

Symptoms Suggestive of Preterm Labour:

• Regular, painful uterine contractions (often >4 in 20 mins or >8 in 60 mins).
• Dull, persistent low backache.
• Pelvic pressure or a sensation of the baby “pushing down”.
• Menstrual-like cramps or abdominal tightening.
• Increase or change in vaginal discharge (mucoid, watery, blood-tinged – “show”).
• Vaginal bleeding (more than a show needs urgent assessment for APH).
• Suspected rupture of membranes (gush or persistent trickle of fluid).

Initial Triage & Assessment (WIPER + ABCDE if unwell):

1. Confirm Gestational Age: Essential. Use LMP and dating scan.
2. Maternal Assessment:
   • History: Focus on symptoms (onset, frequency, intensity of contractions, bleeding, fluid loss, fetal movements), risk factors for PTL, current pregnancy complications.
     Key History Questions (Click to expand)

     • “When did the pains/tightenings start?”
     • “How often are they coming? How long do they last?”
     • “Are they getting stronger or more frequent?”
     • “Have you had any vaginal bleeding or watery loss?” (Quantify if possible)
     • “How are the baby’s movements?”
     • “Do you have any previous history of preterm birth or cervical surgery?”
     • “Any fever, urinary symptoms, or feeling unwell?”
   • Vital Signs: Temperature, pulse, blood pressure, respiratory rate. (Fever/tachycardia may suggest chorioamnionitis).
   • Abdominal Palpation: Assess uterine tone, tenderness, frequency and strength of contractions (palpate during a contraction), fetal lie and presentation (Leopold’s).
3. Fetal Assessment:
   • Cardiotocography (CTG): For at least 20-30 minutes to assess fetal heart rate pattern and uterine activity. This is crucial.
   • Assess fetal movements (as reported by mother and on CTG).
4. Initial Investigations (covered in next section): Speculum, vaginal swabs, consider TVUS/fFN.

Differentiating True vs. False Labour (Braxton Hicks):

Investigations in Suspected Preterm Labour

Investigations aim to confirm PTL, identify potential causes, assess risk of imminent delivery, and guide management.

1. Cardiotocography (CTG):
   • Purpose: Assesses fetal heart rate (FHR) variability, accelerations, decelerations, and baseline rate. Also records uterine activity (frequency, duration, but not intensity).
   • Indication: All women with suspected PTL from viable gestation (usually ≥26 weeks, or per local policy).
   • Interpretation: Look for signs of fetal compromise (e.g., persistent decelerations, reduced variability, tachycardia) which might necessitate urgent delivery. A reassuring CTG is important before considering tocolysis.
2. Sterile Speculum Examination:
   • Purpose:
     • Visualise the cervix: Assess for dilatation, effacement, presence of “show”.
     • Check for pooling of amniotic fluid in the posterior fornix (suggests ROM).
     • Observe for any active bleeding from os.
     • Take swabs:
       • High Vaginal Swab (HVS): For culture and sensitivity (general infection, BV).
       • Group B Streptococcus (GBS) Swab: From lower vagina and rectum if PTL confirmed or PPROM.
       • Fetal Fibronectin (fFN) swab: If indicated (see below).
   • Key Point: Use a dry speculum or one lubricated with water/saline if fFN testing is planned, as gel lubricants can interfere with the test.
3. Digital Vaginal Examination:
   • Purpose: To assess cervical dilatation, effacement, consistency, position, and station of presenting part.
   • Indications: Generally performed if membranes are intact and PTL is strongly suspected or established, to confirm cervical change.
   • Caution: AVOID or perform with extreme caution if PPROM is suspected or confirmed due to risk of introducing infection. Some units defer until a management plan (e.g. induction) is made in PPROM.
   • Key phrase: “I would consider a digital vaginal examination to assess the cervix if membranes are intact and it is clinically indicated to confirm established labour, but I would be cautious if PPROM is suspected.”
4. Transvaginal Ultrasound (TVUS) for Cervical Length:
   Details on TVUS Cervical Length (Click to expand)

   Purpose: Provides an objective and reproducible measure of cervical length. More accurate than digital assessment of length.

   Indications in symptomatic women (NICE):

   • Gestational age 24+0 to 34+6 weeks.
   • Intact membranes.
   • Uncertain diagnosis of PTL (e.g., contractions but cervix appears <3cm dilated on speculum/digital exam).

   Interpretation (general guide, thresholds vary slightly):

   • >30mm: PTL unlikely. Reassuring.
   • 15-29mm: Intermediate risk. May be combined with fFN.
   • <15mm: High risk of preterm birth. Strongly predictive.

   Technique: Empty bladder, TVUS probe in anterior fornix, measure straight length of endocervical canal from internal to external os. Note any funnelling. Obtain 3 measurements over 3-5 mins and take shortest.

5. Fetal Fibronectin (fFN) Test:
   Details on Fetal Fibronectin (fFN) (Click to expand)

   Purpose: fFN is a glycoprotein (“glue”) found at the choriodecidual interface. Its presence in cervicovaginal secretions between 22-35 weeks indicates disruption of this interface and increased risk of PTL.

   Indications (NICE) – for symptomatic women where diagnosis is uncertain:

   • Gestational age 24+0 to 34+6 weeks.
   • Intact membranes.
   • Cervical dilatation <3cm.
   • No significant vaginal bleeding.
   • No sexual intercourse in last 24h.
   • No recent digital vaginal exam (can cause false positives).

   Interpretation:

   • Negative (<50 ng/mL): High negative predictive value (NPV). PTL within 7-14 days is very unlikely. Can help avoid unnecessary admission/interventions.
   • Positive (≥50 ng/mL): Increased risk of PTL. Positive predictive value (PPV) is lower, but warrants closer monitoring/management.

   Key point: Often used in conjunction with TVUS cervical length for better risk stratification.

6. Tests for Rupture of Membranes (if suspected):
   • Clinical signs (pooling, positive Valsalva/cough test).
   • Nitrazine test (pH test – amniotic fluid is alkaline, turns blue; false positives with blood, semen, BV).
   • Ferning test (amniotic fluid crystallises into a fern-like pattern on a slide).
   • Specific biochemical marker tests (e.g., AmniSure®, ROM Plus® – detect PAMG-1 or AFP/IGFBP-1). More accurate than nitrazine/ferning.
7. Maternal Blood Tests:
   • Full Blood Count (FBC): Baseline, check for anaemia, raised WCC (infection).
   • C-Reactive Protein (CRP): Inflammatory marker, may be raised in chorioamnionitis.
   • Urea & Electrolytes (U&Es): Baseline before MgSO4, assess renal function.
   • Group & Save / Crossmatch if APH or high risk of PPH.
8. Urine Tests: Urine dipstick and Midstream Urine (MSU) for culture to rule out UTI.

Management Strategies in Preterm Labour

Management is guided by gestational age, maternal/fetal condition, and local/national guidelines (e.g., NICE, RCOG). Always involve senior obstetricians and neonatologists early.

Core Pharmacological Interventions: The “Big Three”

Other Important Management Aspects:

Management of Preterm Prelabour Rupture of Membranes (PPROM)

PPROM is rupture of fetal membranes before 37 weeks gestation and prior to labour onset. It complicates 2-3% of pregnancies but accounts for a significant proportion of preterm births.

Diagnosis of PPROM:

• History: Sudden gush or persistent leakage of watery fluid.
• Sterile Speculum Examination (SSE):
  • Direct observation of amniotic fluid pooling in the posterior vaginal fornix.
  • Fluid seen leaking from the cervical os (may ask patient to cough/Valsalva).
  • AVOID digital vaginal examination unless in established labour or delivery is planned imminently.
• Confirmatory Tests (if diagnosis uncertain after SSE):
  • Nitrazine Test: Amniotic fluid is alkaline (pH 7.0-7.5), turns yellow nitrazine paper blue. False positives: blood, semen, alkaline antiseptics, bacterial vaginosis.
  • Ferning Test: Amniotic fluid dried on a slide forms a characteristic fern-like pattern due to estrogen and sodium chloride.
  • Biochemical Marker Tests: More specific.
    • PAMG-1 (Placental Alpha Microglobulin-1) tests (e.g., AmniSure®).
    • IGFBP-1 (Insulin-like Growth Factor Binding Protein-1) tests (e.g., Actim® PROM).
• Ultrasound: May show oligohydramnios, but not diagnostic of PPROM on its own.

Initial Management (Admission & Assessment):

1. Confirm diagnosis and gestational age.
2. Admit to hospital.
3. Maternal observations: Temperature, pulse, BP, RR (q4-6h or more frequently if concerns). Monitor for signs of chorioamnionitis (fever, tachycardia, uterine tenderness, foul-smelling discharge, raised WCC/CRP).
4. Fetal assessment: CTG on admission, then daily or as clinically indicated. Regular checks of fetal movements.
5. Investigations:
   • Swabs at SSE: HVS for MCS, GBS swab.
   • Maternal bloods: FBC, CRP (baseline and then serially, e.g., daily or alternate days, if monitoring for infection).

Key Interventions in PPROM (NICE CG13 & NG25):

Timing and Mode of Delivery:

• If Chorioamnionitis Suspected/Confirmed: Expedite delivery regardless of gestation. Administer broad-spectrum IV antibiotics.
• If No Chorioamnionitis:
  • ≥37+0 weeks: Offer induction of labour (IOL) or await spontaneous labour for up to 24h if preferred and no contraindications.
  • 34+0 to 36+6 weeks: Discuss with woman risks/benefits of IOL vs. expectant management. NICE suggests planning for delivery from 34+0 weeks. Many units aim for delivery around 34-36 weeks.
  • <34+0 weeks (expectant management): Continue monitoring. Delivery indicated for:
    • Onset of active labour.
    • Signs of chorioamnionitis.
    • Fetal compromise.
    • Significant APH.
    • Consider IOL if >34 weeks reached during expectant management.
• Mode of Delivery: Vaginal delivery is preferred unless obstetric contraindications exist (e.g., breech presentation at very early GA, fetal distress requiring urgent delivery).

Delivery Considerations & Neonatal Liaison in Preterm Birth

The delivery of a preterm infant requires careful planning and a multidisciplinary approach involving obstetricians, midwives, anaesthetists, and neonatologists.

Liaison with Neonatal Team:

• Early Communication: Inform the neonatal team as soon as preterm birth is anticipated, especially if <34 weeks or if fetal compromise is suspected. Provide details of GA, EFW, maternal condition, and any interventions (steroids, MgSO4).
• Antenatal Counselling: If time permits, involve neonatologists in counselling parents about likely neonatal outcomes, NICU admission, and potential complications.
• Presence at Delivery: Neonatal team (usually registrar/consultant and nurse) should be present at the delivery of very preterm infants (typically <32-34 weeks or if resuscitation anticipated) to provide immediate care.

Mode of Delivery:

• Vaginal Delivery: Generally preferred for preterm infants if no obstetric contraindications. Associated with lower maternal morbidity.
• Caesarean Section (CS):
  • Indications: Same as for term pregnancies (e.g., fetal distress, failed IOL, placenta praevia, some malpresentations).
  • Preterm Breech: Controversial. For very preterm breech (e.g., <28-32 weeks), some evidence suggests CS may improve neonatal outcomes, but this is weighed against increased maternal morbidity. Decision is individualised after senior discussion and parental counselling (see RCOG Greentop Guideline on Breech Presentation). Many units would favour CS for breech <32 weeks.
  • Classical CS: May be required if lower segment is poorly formed (very early GA) to facilitate atraumatic delivery.

Intrapartum Management:

• Fetal Monitoring: Continuous CTG is recommended in established PTL. Be aware that preterm fetuses have less physiological reserve and may show subtle signs of hypoxia earlier. Interpret CTG in context of GA. Scalp electrode if membranes ruptured and CTG difficult to interpret. Fetal blood sampling is rarely performed at very preterm gestations.
• Pain Relief:
  • Entonox, Pethidine/Diamorphine can be used.
  • Epidural analgesia is a good option, can be beneficial if CS becomes necessary. Does not appear to worsen neonatal outcomes in PTL.
• Second Stage: Aim for an atraumatic delivery. Avoid prolonged second stage. Consider episiotomy to facilitate delivery if perineum tight. Instrumental delivery (forceps preferred by some for controlled delivery of preterm head, ventouse also used) if indicated.
• Antibiotics for GBS Prophylaxis: As per PTL/PPROM guidelines.

Immediate Neonatal Care at Delivery:

Complications & Long-term Sequelae of Preterm Birth

Preterm birth is associated with significant risks for both mother and baby, with the severity generally inversely proportional to gestational age at delivery.

Maternal Complications:

• Related to underlying cause of PTL:
  • Chorioamnionitis/Endometritis/Sepsis (if infection is the cause).
  • Complications of APH (e.g., anaemia, shock, DIC if abruption).
  • Complications of pre-eclampsia if this necessitated preterm delivery.
• Related to management:
  • Side effects of tocolytics or MgSO₄.
  • Increased risk of caesarean section and associated morbidity (infection, VTE, haemorrhage, future placental problems).
• Postpartum Haemorrhage (PPH): Uterine atony can be more common.
• Psychological Impact: Anxiety, depression, PTSD, grief (if poor neonatal outcome), bonding difficulties.

Neonatal Complications (Short-Term – often managed in NICU):

These are more common and severe at earlier gestations.

Neonatal Complications (Long-Term Sequelae):

Many preterm infants grow up healthy, but there’s an increased risk of long-term issues:

• Neurodevelopmental Impairment:
  • Cerebral Palsy (CP): Risk significantly increased, especially after IVH/PVL. MgSO₄ aims to reduce this.
  • Cognitive impairment / Learning difficulties.
  • Behavioural problems (e.g., ADHD, autism spectrum disorder).
  • Motor skill delays.
• Chronic Lung Disease (CLD) / Bronchopulmonary Dysplasia (BPD): Especially if required prolonged ventilation.
• Sensory Impairments:
  • Visual problems (ROP sequelae, strabismus, refractive errors).
  • Hearing impairment (requires screening).
• Growth Problems: May have catch-up growth, but some remain smaller.
• Increased risk of adult health problems: E.g., hypertension, metabolic syndrome (later in life).
• Educational and Social Challenges.

OSCE Focus: Preterm Labour Scenarios

PTL OSCE stations typically assess your ability to take a focused history, communicate effectively with a patient (often an actor playing a distressed pregnant woman), outline an initial management plan, and demonstrate safe clinical reasoning.

Structure for a PTL OSCE Station:

1. WIPER: Wash hands, Introduce self (name, role ST1/2 Dr), Patient identity (name, DOB), Explain purpose of consultation & gain Consent, Ensure Privacy & Position (comfortable).
2. Focused History:
   • Presenting complaint: “Tell me what’s brought you in today?” (Contractions – SODA: Site, Onset, Duration, Associated symptoms like bleeding/ROM/pain score; Fetal movements).
   • Gestational age (confirm with LMP & scan).
   • Key risk factors for PTL (previous PTL/surgery, multiples, infections, medical conditions). Key OSCE Phrase: “To help me understand what might be going on, I need to ask you a few questions about this pregnancy and your general health. Is that okay?”
   • Red flags: Fever, heavy bleeding, signs of severe pre-eclampsia.
3. Verbalise Examination (as guided by scenario):
   • “I would first assess your vital signs – pulse, blood pressure, temperature, respiratory rate.”
   • “I would then perform an abdominal examination to assess the baby’s position, feel for contractions, and listen to the baby’s heartbeat using a Sonicaid/CTG.” Key OSCE Phrase: “If there were concerns about whether you are in preterm labour, and with your consent, a doctor might need to perform a speculum examination to look at your cervix and take some swabs. This would be to check if your waters have broken or if there’s any sign of infection, and sometimes a test called fetal fibronectin can help predict the chance of preterm delivery. A transvaginal ultrasound scan might also be offered to measure the length of your cervix.” (Adapt based on scenario cues)
4. Outline Investigations & Initial Management Plan:
   • “Based on what you’ve told me, it sounds like you could be experiencing preterm labour. My immediate plan would be…”
   • CTG monitoring.
   • Bloods (FBC, CRP, U&Es, G&S), urine dip/MSU.
   • Mention specific interventions based on GA and findings:
     • “If you are less than 34 weeks, we would offer you a course of steroid injections to help your baby’s lungs mature.”
     • “If you are between 24 and 34 weeks, we might also offer medication called tocolysis, like Nifedipine tablets, to try and slow down the contractions for a short while, to allow the steroids to work and for us to make other plans if needed, like transferring you to a hospital with a specialist baby unit.”
     • “If delivery seems likely before 30 weeks (or 34 weeks depending on local guidelines), we would also offer you an infusion of magnesium sulphate to help protect your baby’s brain.”
   • Involve seniors: Key OSCE Phrase: “I would discuss your case immediately with my senior registrar and the consultant obstetrician, and we would also liaise with the neonatal team (baby doctors).”
5. Communication and Empathy:
   • Acknowledge patient’s anxiety: “I can see this is a worrying time for you.”
   • Explain clearly, avoid jargon. Check understanding: “Does that make sense?” “Do you have any questions so far?”
   • Involve patient in decisions where appropriate.
   • Offer support.
6. Summarise and Safety Net:
   • Briefly recap the plan.
   • If discharged (e.g., threatened PTL that settles): Clear instructions on when to return.

Case-Based Discussion (CBD) Guide: Preterm Labour

A CBD on PTL assesses your clinical reasoning, decision-making, and application of knowledge in a specific case you’ve managed (or observed). It’s a reflective discussion, not a direct test of knowledge recall like an MCQ, but your knowledge underpins your reasoning.

Preparing for a PTL CBD:

1. Choose a suitable case: One that involved diagnostic challenges, management decisions, ethical considerations, or multidisciplinary input.
2. Know the case thoroughly: Dates, times, patient history, investigations, results, decisions made, outcomes. Review the patient’s notes.
3. Review relevant guidelines: NICE (CG13, NG25), RCOG Green-top Guidelines related to PTL, PPROM, MgSO4, GBS.
4. Reflect on your role: What did you do? What decisions did you contribute to? What did you learn?
5. Anticipate questions: Think about why certain decisions were made, what alternatives were considered, and the evidence base.

Common Themes & Potential Questions in a PTL CBD:

• Diagnosis:
  • “How did you confirm the diagnosis of PTL in this patient?”
  • “What was your reasoning for performing/not performing a fetal fibronectin test or TVUS cervical length?”
  • “What were the differential diagnoses you considered?”
• Risk Assessment:
  • “What were the key risk factors for PTL in this patient?”
  • “How did these risk factors influence your management plan?”
• Management Decisions (Rationale & Evidence):
  • “Why were antenatal corticosteroids given? What is the evidence for their use?” (Mention specific benefits like RDS, IVH, NEC reduction).
  • “What tocolytic was used, and why was that particular agent chosen? What are the alternatives and their pros/cons?” (Discuss Nifedipine vs Atosiban, contraindications).
  • “Was magnesium sulphate administered? What was the indication and evidence base? How was the patient monitored for toxicity?”
  • “Were antibiotics given? What was the indication?” (GBS, PPROM, chorioamnionitis).
  • “What was the plan for in-utero transfer, if relevant?”
• Complications & Contingency Planning:
  • “What potential maternal or fetal complications were you anticipating or monitoring for?”
  • “How would your management have changed if [e.g., the CTG became pathological, or the mother developed a fever]?”
• Multidisciplinary Team Working:
  • “Who else was involved in this patient’s care? How did you communicate with them?” (Seniors, neonatologists, midwives, anaesthetists).
• Communication & Ethics:
  • “How was the situation explained to the patient and her family? What were their main concerns?”
  • “Were there any ethical dilemmas, particularly regarding gestational age and viability?” (e.g., for extremely preterm cases).
• Reflection & Learning:
  • “What did you learn from this case?”
  • “Is there anything you would do differently next time?”
  • “How does this case relate to clinical governance or patient safety?”

Structure of Your CBD Responses:

• Be clear and concise.
• Justify your actions/decisions with clinical reasoning and evidence/guidelines. Key CBD Phrase: “My rationale for this decision was based on [NICE guidelines / RCOG recommendations / the patient’s specific clinical picture] which suggests…”
• Acknowledge alternatives: “An alternative approach could have been X, however, we chose Y because…”
• Demonstrate insight and reflection. Show you understand the bigger picture.
• Be honest. If you’re unsure about something, say so, but explain how you would find out.

Flashcards: Preterm Labour Management (Expanded)

Click on each card to reveal the answer. Test your recall of key facts for PTL.

Clinical Presentation and Diagnostic Approach

The clinical presentation of PCOS is highly variable. A thorough history and examination are crucial for suspecting the diagnosis and guiding investigations.

Comprehensive History Taking:

• Menstrual History:
  • Age of menarche.
  • Detailed cycle pattern: Oligomenorrhoea (cycle length >35 days or <8 cycles/year), amenorrhoea (absence of menses for ≥3-6 months in a woman with previous cycles, or by age 15 if no menarche).
  • Duration and volume of bleeding.
• Hyperandrogenism Features:
  • Hirsutism: Onset, progression, severity, location (face, chest, back, abdomen). Key Exam Phrase: “Can you describe any unwanted hair growth you’ve noticed?”. Consider using the modified Ferriman-Gallwey score (mFG ≥8 often indicative).
  • Acne: Persistent, severe, or adult-onset acne, often resistant to standard treatments.
  • Androgenic Alopecia: Male-pattern hair loss (frontal/temporal thinning, vertex).
  • Red Flag: Rapid onset/virilisation (clitoromegaly, voice deepening, increased muscle mass) suggests an androgen-secreting tumour.
• Reproductive History:
  • History of subfertility or infertility.
  • Previous pregnancies: Complications like gestational diabetes (GDM), pre-eclampsia, preterm birth.
• Metabolic Features & Risk Factors:
  • Weight history: Obesity, central adiposity, difficulty losing weight.
  • Symptoms of insulin resistance: Acanthosis nigricans (velvety, hyperpigmented skin in flexures), skin tags.
  • Symptoms suggestive of obstructive sleep apnoea (OSA): Snoring, daytime somnolence, witnessed apnoeas.
  • Family history: PCOS, T2DM, premature cardiovascular disease (CVD), dyslipidaemia, hypertension.
• Psychological Impact:
  • Screen for anxiety, depression, body image issues, eating disorders. Key Exam Phrase: “How has this been affecting your mood or self-esteem?”
• Lifestyle Factors: Diet, physical activity, smoking, alcohol.
• Medication History: Including hormonal contraceptives, supplements.

Physical Examination:

• General: BMI, waist circumference (marker of central adiposity).
• Signs of Hyperandrogenism: Assess for hirsutism (distribution/severity), acne, alopecia.
• Signs of Insulin Resistance: Acanthosis nigricans (neck, axillae, groin), skin tags.
• Blood Pressure.
• Thyroid examination (if clinically indicated).
• Signs of Virilisation (if history suggestive).

Differential Diagnosis – Conditions to Exclude:

It’s crucial to exclude other conditions that can mimic PCOS features:

Investigations for PCOS

Investigations aim to:

1. Confirm features of PCOS (hyperandrogenism, anovulation).
2. Exclude other disorders mimicking PCOS.
3. Assess for associated metabolic abnormalities.

1. Hormonal Assessment:

(Ideally performed in the early follicular phase, days 2-5 of the menstrual cycle if cycling, or randomly if amenorrhoeic. Fasting sample often preferred for some tests).

• To assess hyperandrogenism:
  • Total Testosterone: Often mildly elevated.
  • Sex Hormone Binding Globulin (SHBG): Typically low in PCOS (due to hyperinsulinaemia and hyperandrogenaemia).
  • Free Androgen Index (FAI): Calculated as (Total Testosterone / SHBG) x 100. More sensitive marker of bioavailable testosterone than total testosterone alone. FAI >4-5 is often considered elevated.
  • Consider DHEAS if adrenal source of androgens suspected, though less common.
• To assess ovulatory function & HPO axis:
  • Luteinizing Hormone (LH) & Follicle-Stimulating Hormone (FSH): LH may be elevated, FSH normal or low, leading to an increased LH:FSH ratio (e.g., >2 or >3). However, this is not a diagnostic criterion and is not consistently present.
  • Progesterone: Mid-luteal phase (day 21 of a 28-day cycle, or 7 days before expected menses) progesterone can confirm ovulation (>30 nmol/L suggests ovulation). Serial measurements may be needed if cycles are irregular.
• To exclude other conditions:
  • Thyroid Stimulating Hormone (TSH): To exclude thyroid dysfunction.
  • Prolactin: To exclude hyperprolactinaemia. (Repeat if mildly elevated, ensure non-stressed sample).
  • 17-Hydroxyprogesterone (17-OHP): Early morning, follicular phase sample. Essential if NCCAH is suspected (e.g., specific ethnicity, severe/rapid onset hyperandrogenism, family history). Values >5-15 nmol/L may warrant ACTH stimulation test.
• Anti-Müllerian Hormone (AMH):
  • Typically elevated in PCOS due to increased number of small antral follicles.
  • Not currently part of diagnostic criteria but can be a useful marker of ovarian reserve and may correlate with PCOM severity. Its role in routine PCOS diagnosis is evolving.

2. Pelvic Ultrasound:

• Transvaginal Ultrasound (TVUS): Preferred method for assessing ovarian morphology and endometrial thickness.
  • PCOM Criteria: ≥12 antral follicles (2-9mm in diameter) in at least one ovary, AND/OR ovarian volume >10mL in at least one ovary. (Using modern high-resolution probes, some guidelines suggest a higher follicle count threshold e.g. ≥20 or ≥25).
  • Endometrial Thickness: Important to assess, especially in oligo/amenorrhoea, due to risk of endometrial hyperplasia. Thickness >10-15mm in an anovulatory patient may warrant further investigation (e.g., endometrial biopsy).
• Transabdominal Ultrasound: Alternative if TVUS is not acceptable or feasible (e.g., virginal patients), but less accurate for follicle counting.
• Important Note: PCOM on ultrasound is common in asymptomatic women. It must be interpreted in clinical context. Not recommended for diagnosis within 8 years of menarche due to high incidence of multifollicular ovaries in adolescence.

3. Metabolic Screening (Essential for ALL women diagnosed with PCOS):

• Oral Glucose Tolerance Test (OGTT):
  • 75g OGTT (fasting and 2-hour glucose): Gold standard for detecting impaired glucose tolerance (IGT) and T2DM. Recommended at diagnosis for all women with PCOS.
  • Repeat frequency depends on risk factors (e.g., BMI >25, family history of T2DM, history of GDM) – typically every 1-3 years.
• HbA1c: Can be used as an alternative or adjunct to OGTT, but less sensitive for IGT. May be useful for monitoring.
• Fasting Lipid Profile: Total cholesterol, LDL-C, HDL-C, triglycerides. Dyslipidaemia is common.
• Blood Pressure Measurement.
• Assessment of other cardiovascular risk factors.

Multifaceted Management of PCOS

Management of PCOS is lifelong and should be tailored to the individual’s phenotype, symptoms, concerns (e.g., hirsutism, infertility, metabolic health), and life stage. A multidisciplinary team approach is often optimal.

1. Lifestyle Modification (Cornerstone of Management):

This is first-line for all women with PCOS, especially those overweight or obese.

• Weight Management:
  • Even modest weight loss (5-10% of body weight) can significantly improve menstrual regularity, insulin sensitivity, hyperandrogenism, fertility outcomes, and psychological well-being.
  • Diet: No single diet is superior. Focus on a balanced, calorie-controlled diet (e.g., deficit of 500-750 kcal/day). Low glycaemic index (GI) diets may offer additional benefits for insulin sensitivity. Emphasise whole grains, fruits, vegetables, lean protein, healthy fats.
  • Exercise: Aim for at least 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity aerobic exercise per week, PLUS muscle-strengthening activities on 2 or more days a week. Reduce sedentary behaviour.
• Smoking Cessation: Smoking can worsen metabolic and cardiovascular risks.
• Stress Management & Sleep Hygiene: Important for overall well-being.

2. Management of Menstrual Irregularity & Endometrial Protection:

(For women not currently seeking pregnancy)

• Combined Oral Contraceptive Pills (COCPs):
  • First-line pharmacological option. Regulate cycles, reduce hirsutism/acne (by increasing SHBG and suppressing ovarian androgen production), and provide endometrial protection.
  • Low-dose oestrogen (e.g., 20-35 mcg ethinylestradiol) with a non-androgenic or anti-androgenic progestin (e.g., drospirenone, cyproterone acetate – though co-cyprindiol has higher VTE risk and is usually second-line for acne/hirsutism).
  • Discuss benefits, risks (VTE, cardiovascular in some), and contraindications.
• Cyclical Progestogens:
  • E.g., Medroxyprogesterone acetate 10mg daily or Norethisterone 5mg daily for 12-14 days each month/2 months to induce a withdrawal bleed if COCPs are contraindicated or not desired.
  • Provides endometrial protection but does not address hyperandrogenic symptoms or provide contraception.
• Levonorgestrel-releasing Intrauterine System (LNG-IUS, e.g., Mirena):
  • Provides excellent endometrial protection and can reduce menstrual bleeding.
  • Does not typically regulate cycles or improve hyperandrogenic symptoms systemically. Offers contraception.

3. Management of Hyperandrogenism (Hirsutism, Acne, Alopecia):

• COCPs: As above, often first-line. Improvement may take 6-12 months.
• Anti-androgens: (Usually initiated by specialists, used in conjunction with effective contraception due to teratogenicity).
  • Spironolactone: (50-200 mg/day) Aldosterone antagonist with anti-androgenic properties. Effective for hirsutism. Monitor potassium.
  • Cyproterone Acetate: Potent anti-androgen, available in some COCPs (e.g., co-cyprindiol/Dianette) or as a standalone. Higher VTE risk with co-cyprindiol.
  • Finasteride/Dutasteride: 5-alpha-reductase inhibitors. Can be used for hirsutism or androgenic alopecia, often off-label.
• Topical Treatments:
  • Eflornithine cream: For facial hirsutism (slows hair growth).
  • Standard acne treatments (topical retinoids, benzoyl peroxide, topical/oral antibiotics). Isotretinoin for severe acne (specialist use, requires strict contraception).
• Cosmetic Measures: Shaving, waxing, plucking, electrolysis, laser hair removal (can be very effective).

4. Management of Infertility due to Anovulation:

5. Management of Metabolic Complications:

• Insulin Resistance / Impaired Glucose Tolerance / T2DM:
  • Lifestyle modification is paramount.
  • Metformin: Consider if IGT or T2DM diagnosed, or in selected high-risk individuals. Improves insulin sensitivity, may aid weight management, and can improve menstrual cyclicity in some.
• Dyslipidaemia: Lifestyle changes. Statins if indicated based on cardiovascular risk assessment.
• Hypertension: Lifestyle changes. Antihypertensive medication as per guidelines.

6. Psychological Well-being:

• Screen for anxiety, depression, eating disorders, and body image concerns.
• Offer psychological support, counselling, or referral to mental health services.
• Patient support groups can be beneficial.

Long-Term Health Implications and Follow-up

PCOS is a lifelong condition with significant potential long-term health risks. Proactive screening and management are essential.

Follow-up Strategy:

• Individualised Plan: Based on phenotype, age, risk factors, and patient preferences.
• Regular Review: At least annually for most, more frequently if actively managing fertility, metabolic issues, or significant symptoms.
• Multidisciplinary Team (MDT) Approach: May involve GP, endocrinologist, gynaecologist, dietitian, psychologist, fertility specialist.
• Key Areas for Monitoring:
  • Menstrual cycle pattern.
  • Hyperandrogenic symptoms.
  • Weight/BMI, waist circumference.
  • Blood pressure.
  • Glucose tolerance (OGTT/HbA1c).
  • Lipid profile.
  • Psychological well-being.
  • Symptoms of OSA.
• Patient Education & Empowerment: Crucial for long-term adherence and self-management. Provide reliable information resources.

OSCE Focus & Communication Skills in PCOS

PCOS stations in OSCEs can test various skills: history taking, explaining diagnosis, counselling on management (lifestyle, medical, fertility), discussing long-term risks, and addressing psychological impact.

Common PCOS OSCE Scenarios:

• Taking a focused history from a patient with irregular periods and hirsutism.
• Explaining a new diagnosis of PCOS to a young woman.
• Counselling a patient with PCOS on lifestyle modifications.
• Discussing fertility options for a couple where the woman has PCOS.
• Managing a patient’s concerns about long-term health risks of PCOS.
• Addressing body image issues or mood changes in a patient with PCOS.

Key Communication Strategies (SPIKES/BREAKS framework can be adapted):

1. Setting & Preparation (S/B): Ensure privacy, review notes if possible.
2. Perception (P/R): Start by understanding the patient’s perspective. “What are your main concerns today?” “What do you understand so far about PCOS?” (ICE: Ideas, Concerns, Expectations).
3. Invitation/Information (I/E): Ask permission to share information. Give information in small chunks, check understanding. Use clear, simple language. Avoid jargon.
4. Knowledge/Giving Information (K/A):
   • When explaining diagnosis: Use Rotterdam criteria simply. Emphasise it’s a syndrome.
   • When discussing management: Offer choices, discuss pros/cons (shared decision-making). Start with lifestyle.
   • When discussing risks: Be honest but sensitive. Frame positively (risks can be managed).
5. Empathy & Emotions (E/K): Acknowledge and validate emotions. “I can see this is a lot to take in.” “It’s understandable to feel worried/frustrated.” Use empathetic statements. Non-verbal cues are important.
6. Strategy & Summary (S/S): Summarise key points. Formulate a clear plan together. Provide written information/resources. Safety net and arrange follow-up. “So, to summarise, our plan is…” “Do you have any questions about what we’ve discussed?”

Case-Based Discussion (CBD) Focus: PCOS

A CBD on PCOS will assess your clinical reasoning, application of knowledge, and understanding of management principles in the context of a specific patient case.

Example CBD Case Snippet:

“You are discussing a 26-year-old woman, Aisha, who was diagnosed with PCOS two years ago. Her BMI is 34. She initially presented with oligomenorrhoea and moderate hirsutism. She was started on a COCP which regulated her cycles and slightly improved her hirsutism. She now wishes to conceive. Her recent HbA1c was 45 mmol/mol (pre-diabetic range). She is very anxious about her ability to get pregnant and her long-term health.”

Potential CBD Discussion Points (using the above case as an example):

1. Review of Diagnosis:
   • “How was Aisha’s diagnosis of PCOS originally established? What criteria were met?”
   • “Were appropriate differential diagnoses excluded at the time?”
2. Assessment of Current Status & Concerns:
   • “What are Aisha’s main concerns now?” (Fertility, pre-diabetes, anxiety).
   • “How would you further assess her current hyperandrogenic symptoms and metabolic status?”
3. Pre-conception Management:
   • “What advice and interventions would you prioritise before she actively tries to conceive?” (Weight management, optimising glycaemic control, folic acid 5mg, smoking/alcohol, review medications).
   • “Discuss the role of lifestyle changes and Metformin in her pre-conception plan.”
4. Fertility Management Strategy:
   • “What are the first-line ovulation induction agents for Aisha once pre-conception optimisation is addressed? Discuss the evidence for letrozole vs. clomiphene.”
   • “How would you monitor ovulation induction? What are the risks?”
   • “When would you consider second-line treatments or referral to a fertility specialist?”
5. Management of Metabolic Comorbidities:
   • “How would you manage her pre-diabetes (HbA1c 45 mmol/mol)?”
   • “What long-term metabolic screening does she require?”
6. Addressing Psychological Impact:
   • “How would you address Aisha’s anxiety about fertility and her health?”
7. Evidence-Base & Guidelines:
   • “What national/international guidelines inform your management of PCOS and associated infertility/metabolic issues?” (e.g., NICE, ESHRE/ASRM).
8. Multidisciplinary Team Involvement:
   • “Who else might be involved in Aisha’s care?” (Dietitian, endocrinologist, fertility specialist, psychologist).
9. Reflection & Learning:
   • “What are the key learning points from this case?”
   • “Are there any aspects of her care you would manage differently in retrospect?”

The MDT offers resources and courses to help you prepare for CBDs and other workplace-based assessments.

Flashcards: PCOS Rapid Review

Click on each card to reveal the answer. Test your core knowledge!

The MDT offers extensive flashcard decks and other learning tools for PLAB/MLA/MSRA and specialty exams. Check our website for more!

Comprehensive Information Gathering: The Foundation

A meticulous history is paramount for safe and personalised contraceptive advice.

Detailed History Components:

• Reason for Consultation: “What brings you here today to discuss contraception?” (e.g., starting, switching, problems, EC).
• Ideas, Concerns, Expectations (ICE):
  Explore ICE (Click to Expand)

  Ideas: “What do you already know about contraception?” “Have you used any methods before?” “What have you heard from friends/family/internet?”

  Concerns: “Is there anything you’re particularly worried about regarding contraception (e.g., side effects, hormones, procedures)?”

  Expectations: “What are you hoping to get from a contraceptive method?” “What are your priorities (e.g., effectiveness, ease of use, effect on periods)?”

• Menstrual History: LMP, cycle length/regularity, flow (heavy/painful periods might influence choice, e.g., IUS).
• Obstetric History: Gravidity, parity, mode of delivery, complications (e.g., postpartum haemorrhage, pre-eclampsia). Timing since last pregnancy. Breastfeeding status.
• Gynaecological History: Previous contraception (type, experience, side effects), STIs (history, current risk), PID, ectopic pregnancy, cervical screening (date, result, follow-up), fibroids, endometriosis, ovarian cysts.
• Medical History (UKMEC Critical):
  • Cardiovascular: Hypertension (current BP reading essential), VTE (personal/family Hx), IHD, stroke, valvular heart disease, clotting disorders.
  • Migraine: With or without aura (aura is key for CHC contraindication).
  • Cancer: Breast (current/past/family Hx of BRCA), gynaecological cancers.
  • Metabolic: Diabetes (type, duration, control, complications), BMI (calculate or ask height/weight).
  • Liver/Gallbladder: Active liver disease, cholestasis of pregnancy.
  • Other: Epilepsy, depression/mood disorders, malabsorption syndromes, organ transplant.
• Medications & Allergies: Prescribed, OTC, herbal (e.g., St John’s Wort – enzyme inducer). Specifically ask about enzyme-inducing drugs. Allergies (e.g., latex, copper, specific hormones).
• Family History: VTE, inherited thrombophilias, breast/ovarian cancer (especially early onset).
• Social History: Age, smoking (quantity), alcohol, recreational drugs. Relationship status, partner involvement (if patient wishes). Future fertility plans (short/long term). Lifestyle (e.g., shift work, travel – impacts pill taking). Safeguarding concerns.
• Sexual History: Number of partners, gender of partners, type of sex, risk of STIs. Consistent condom use.

In-Depth Discussion of Contraceptive Methods

Provide balanced information, focusing on methods suitable for the individual based on their history and preferences. Always discuss effectiveness with typical use rates primarily, mentioning perfect use for context.

Long-Acting Reversible Contraception (LARCs)

Generally first-line due to high effectiveness and user-independence.

Shorter-Acting Hormonal Methods

Barrier Methods & Others

Contraception in Special Circumstances

Tailoring advice for specific patient groups and situations is crucial.

OSCE & CBD Strategy for Contraceptive Counselling

These stations assess communication, clinical reasoning, application of guidelines (UKMEC), and patient-centred care.

OSCE Station Approach:

1. Preparation (Pre-Station): Briefly review common contraceptive methods and UKMEC red flags.
2. Introduction (WIPE & Rapport): Wash hands, Introduce, Patient ID, Explain purpose & duration, Consent. “Hi, I’m Dr. X, one of the junior doctors. Can I confirm your name and DOB? Today we have about [time] minutes to discuss contraception. Is that okay?” Smile, open body language.
3. Information Gathering (CHOICES – ‘H’ & ‘C’ for Concerns):
   • Start open: “What brings you in today regarding contraception?” “What are your thoughts/ideas about it?” (ICE)
   • Systematic history: Use the CHOICES mnemonic as a checklist. Prioritise UKMEC questions. “To advise you best, I need to ask some questions about your health, periods, and lifestyle. Some may be personal, but it’s all confidential.”
   • Key Exam Phrases for History:
     • “Do you suffer from migraines? If so, do you ever get any warning signs before the headache, like flashing lights or zig-zag lines?” (Aura)
     • “Have you or anyone in your close family ever had a blood clot in the leg or lung?” (VTE)
     • “Do you smoke? If so, how many per day?” (Crucial for CHC)
     • “What is your current height and weight, if you know it?” (For BMI)
     • “Are you taking any regular medications, including anything over the counter or herbal remedies?” (Enzyme inducers)
4. Explaining Options & Information (CHOICES – ‘O’ & ‘I’):
   • “Based on what you’ve told me, there are several good options we could consider. These include long-acting methods like the implant or coil, and shorter-acting methods like the pill.”
   • Discuss 2-3 suitable methods. Start with LARCs if appropriate. For each: Mechanism (briefly), Effectiveness (typical use), Key Pros & Cons (tailored), Common Side Effects, How it’s used/fitted.
   • Use patient leaflets if available (verbalise this).
5. Checking Understanding & Empowering Choice (CHOICES – ‘C’ & ‘E’):
   • “What are your thoughts on those options?” “Does one appeal more than others?” “Do you have any questions about what we’ve discussed?”
   • “It’s your decision, and I’m here to help you choose what’s best for you.”
6. Safety Netting & Follow-up (CHOICES – ‘E’ & ‘S’):
   • If method chosen: Explain start-up, missed pill rules, warning signs (e.g., ACHES for CHC, signs of IUD expulsion/infection).
   • “It’s important to remember that while this method is excellent for preventing pregnancy, it doesn’t protect against sexually transmitted infections. If you’re at risk, using condoms is also important. We can also discuss STI screening.”
   • Arrange follow-up (e.g., IUD fitting, BP check for CHC, 3-month review for new pill). Provide written information.
7. Summarise and Close: “So, to summarise… Are you happy with that plan?”

Common OSCE Pitfalls & Things to Avoid:

• Not eliciting/addressing ICE.
• Being too didactic/doctor-centred; not facilitating shared decision-making.
• Missing crucial UKMEC contraindications (especially for CHC).
• Insufficient discussion of side effects or risks.
• Forgetting STI discussion and condom advice.
• Poor or absent safety netting (e.g., missed pill rules, when to seek help).
• Running out of time due to poor structure or getting bogged down.
• Using medical jargon without explanation.
• Not checking patient understanding.

How to Excel in OSCEs:

• Excellent communication: Active listening, empathy, clear non-judgmental language.
• Structured approach (e.g., CHOICES).
• Confident application of UKMEC.
• Tailor advice specifically to the patient’s scenario.
• Empower the patient.
• Thorough safety netting and clear follow-up.
• Good time management.
• Offer patient information leaflets (even if simulated).

Practice with The MDT’s OSCEbot for realistic, interactive scenarios.

Flashcards: Contraceptive Counselling Key Facts

Click on each card to reveal the answer. Test your rapid recall!